Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Compare Best Stocks
Joshua Schimmer's Stock Ratings
Cantor Fitzgerald Analyst
Joshua Schimmer is an analyst at Cantor Fitzgerald. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 12/17/2025
Updated: Dec 17, 2025
Overall Average Return
-6.96%
Smart Score
Overall Average Return Percentile
21st
Number of Ratings
34
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 04/05/2024 | CABA | Buy Now | Cabaletta Bio | $2.44 | 1952.46% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert | |
| 03/22/2024 | CABA | Buy Now | Cabaletta Bio | $2.44 | 1952.46% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert | |
| 11/15/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $67.05 | -25.43% | → $50 | Reiterates | Overweight → Overweight | Get Alert | |
| 11/15/2023 | CABA | Buy Now | Cabaletta Bio | $2.44 | 1952.46% | $40 → $50 | Maintains | Overweight | Get Alert | |
| 10/24/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $67.05 | -25.43% | → $50 | Initiates | → Overweight | Get Alert | |
| 10/24/2023 | CABA | Buy Now | Cabaletta Bio | $2.44 | 1541.97% | → $40 | Initiates | → Overweight | Get Alert | |
| 07/27/2023 | OTIS | Buy Now | Otis Worldwide | $87.96 | 4.59% | $91 → $92 | Maintains | Equal-Weight | Get Alert | |
| 07/12/2023 | OTIS | Buy Now | Otis Worldwide | $87.96 | 3.46% | $91 → $91 | Reiterates | Equal-Weight → Equal-Weight | Get Alert | |
| 04/27/2023 | OTIS | Buy Now | Otis Worldwide | $87.96 | 3.46% | $90 → $91 | Maintains | Equal-Weight | Get Alert | |
| 04/19/2023 | OTIS | Buy Now | Otis Worldwide | $87.96 | 2.32% | $89 → $90 | Maintains | Equal-Weight | Get Alert | |
| 03/31/2023 | RNA | Buy Now | Avidity Biosciences | $71.99 | -72.22% | → $20 | Downgrade | Outperform → In-Line | Get Alert | |
| 03/13/2023 | SGEN | Buy Now | Seagen | — | — | $175 → $229 | Downgrade | Outperform → In-Line | Get Alert | |
| 03/10/2023 | BNOX | Buy Now | Bionomics | — | — | → $6 | Upgrade | In-Line → Outperform | Get Alert | |
| 03/03/2023 | NBIX | Buy Now | Neurocrine Biosciences | $148.74 | -12.6% | → $130 | Upgrade | In-Line → Outperform | Get Alert | |
| 02/28/2023 | DNLI | Buy Now | Denali Therapeutics | $17.56 | 184.74% | $80 → $50 | Maintains | Outperform | Get Alert | |
| 01/24/2023 | TGTX | Buy Now | TG Therapeutics | $30.79 | -18.8% | $16 → $25 | Maintains | Outperform | Get Alert | |
| 12/30/2022 | TGTX | Buy Now | TG Therapeutics | $30.79 | -48.04% | $11 → $16 | Maintains | Outperform | Get Alert | |
| 12/20/2022 | BNOX | Buy Now | Bionomics | — | — | $17 → $6 | Downgrade | Outperform → In-Line | Get Alert | |
| 10/26/2022 | MYOV | Buy Now | Myovant Sciences | — | — | → $27 | Downgrade | Outperform → In-Line | Get Alert | |
| 09/30/2022 | RCKT | Buy Now | Rocket Pharmaceuticals | $3.48 | 2055.17% | $65 → $75 | Maintains | Outperform | Get Alert | |
| 12/01/2021 | TGTX | Buy Now | TG Therapeutics | $30.79 | 16.92% | $55 → $36 | Maintains | Outperform | Get Alert | |
| 03/01/2021 | BMRN | Buy Now | Biomarin Pharmaceutical | $51.77 | 93.16% | $90 → $100 | Upgrade | In-Line → Outperform | Get Alert | |
| 02/25/2020 | REGN | Buy Now | Regeneron Pharmaceuticals | $746.36 | — | — | Upgrade | In-Line → Outperform | Get Alert | |
| 02/03/2020 | BLUE | Buy Now | bluebird bio | — | — | $86 → $100 | Upgrade | In-Line → Outperform | Get Alert | |
| 12/16/2019 | REGN | Buy Now | Regeneron Pharmaceuticals | $746.36 | — | — | Downgrade | Outperform → In-Line | Get Alert | |
| 11/19/2019 | BLUE | Buy Now | bluebird bio | — | — | → $86 | Downgrade | Outperform → In-Line | Get Alert | |
| 05/31/2018 | INCY | Buy Now | Incyte | $97.03 | -12.4% | → $85 | Assumes | → Overweight | Get Alert | |
| 01/23/2018 | BIVV | Buy Now | Bioverativ | — | — | — | Downgrade | Overweight → Neutral | Get Alert | |
| 10/27/2017 | GEMP | Buy Now | Gemphire Therapeutics | — | — | → $22 | Assumes | → Overweight | Get Alert | |
| 10/23/2017 | BIVV | Buy Now | Bioverativ | — | — | → $71 | Assumes | Overweight → Overweight | Get Alert | |
| 04/17/2017 | INCY | Buy Now | Incyte | $97.03 | 27.8% | → $124 | Downgrade | Overweight → Neutral | Get Alert | |
| 04/10/2017 | GEMP | Buy Now | Gemphire Therapeutics | — | — | → $30 | Initiates | → Overweight | Get Alert | |
| 02/28/2017 | BIVV | Buy Now | Bioverativ | — | — | — | Upgrade | Neutral → Overweight | Get Alert | |
| 11/26/2013 | INCY | Buy Now | Incyte | $97.03 | — | — | Assumes | → Overweight | Get Alert |
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2025 Benzinga | All Rights Reserved